We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Supergen, Inc. (MM) | NASDAQ:SUPG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.03 | 0 | 01:00:00 |
SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to discovery and development of novel cancer therapies, announced that it will release its 2011 second quarter financial results on Wednesday, August 3, 2011. SuperGen's new management team will provide details of the Company's financial results and revised outlook for the future.
A press release will be issued at 5:00 a.m. PST on August 3rd. The Company will host a webcast conference call to discuss the results one hour later at 6 a.m. PST. A live webcast of the call will be available in the Investor Events section of the Company's website at www.supergen.com. A webcast replay of the live conference call will be available shortly following the event. Alternatively, you may access a replay of the conference call by dialing (855) 859-2056 (domestic) and (404) 537-3406 (international); replay passcode number is 85860139. The webcast replay and conference call replay will be available for 30 days.
About SuperGen
SuperGen is a pharmaceutical company dedicated to discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. On July 20, 2011 SuperGen closed the transaction to acquire Astex Therapeutics Limited, a privately held, UK-based biotechnology company developing targeted therapies.
For more information about SuperGen, please visit http://www.supergen.com.
1 Year Supergen, Inc. (MM) Chart |
1 Month Supergen, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions